Bespak
Bespak achieves sustainability milestone with first life cycle assessment for pressurised Metered Dose Inhaler valve
1 May 2025, Holmes Chapel, UK — Bespak, a specialist inhalation contract development and manufacturing organisation (CDMO), today announced that it has completed its first life cycle assessment (LCA) for its market-leading BK357 pressurised Metered Dose Inhaler (pMDI) valve. This important step comes as a result of Bespak’s commitment to looking beyond low Global Warming...
Bespak and OzUK further strengthen pressurised Metered Dose Inhaler product development partnership with low Global Warming Potential propellant capability enhancements
10 December 2024 – Holmes Chapel, UK, and Chippenham, UK — Bespak, a specialist inhalation contract development and manufacturing organisation (CDMO), and OzUK, an independent contract research organisation (CRO) specialising in pressurised Metered Dose Inhaler (pMDI) development, today announced additional capability to strengthen their partnered early-stage product feasibility and development service for customers. This announcement...
Bespak and Orbia Fluor & Energy Materials unite to accelerate transition to climate-friendly inhalers
Collaboration aims to speed the commercialisation of low global warming potential pMDIs utilising Orbia Fluor & Energy Materials’ Zephex® 152a propellant at Bespak’s Holmes Chapel site 6 November 2024 – Holmes Chapel, UK, and Boston, US – Bespak, a specialist inhalation contract development and manufacturing organisation (CDMO), and Orbia Advance Corporation, S.A.B. de C.V. (BMV:...
Bespak & H&T Presspart announce availability of GMP pilot line for low GWP pMDIs
Filling line is on track to supply clinical trial batches utilising climate-friendly propellants HFA-152a and HFO-1234ze 8 October 2024 – Holmes Chapel, UK, and Blackburn, UK – Bespak, a specialist inhalation contract development and manufacturing organisation (CDMO), and H&T Presspart, a market leader in the development, manufacturing and supply of inhaled drug delivery components and...
Bespak reaches key milestone in the expansion of its manufacturing capacity, with further expansion plans underway to meet global customer demand for climate friendly inhalers
11 June 2024 – Holmes Chapel, UK – Bespak, a leading contract development and manufacturing organisation (CDMO) focused on orally inhaled and nasal drug-device combination products, is today announcing progress in its commitment to the production of low global warming potential (GWP) pressurised metered dose inhalers (pMDIs) with the arrival of its new high-speed commercial...
DevPro Biopharma and Bespak complete early feasibility studies for new groundbreaking Albuterol Inhaler Ventolin-equivalent pMDI utilides near-zero global warming potential propellant
7 May 2024 – Basking Ridge, NJ, US and Holmes Chapel, UK – DevPro Biopharma and Bespak have announced the completion of early feasibility studies on DP007, a new formulation of albuterol in a pressurised metered dose inhaler (pMDI) which shows comparable performance to Ventolin HFA but with a significant reduction in greenhouse gas emissions....
Bespak and H&T Presspart enter into collaboration agreement to advance transition to low GWP propellants in pMDIs
Partnership will provide GMP filling capabilities and development support for clinical trial programmes with low GWP propellants 3 May 2024 -- Holmes Chapel, UK, and Blackburn, UK -- Bespak, a leading contract development and manufacturing organisation (CDMO) focused on orally inhaled and nasal drug-device combination products, and H&T Presspart, a market leader in the development,...
Bespak and Medicines Evaluation Unit collaborate to accelerate clinical trials on climate-friendly inhalers
Relationship will provide pharmaceutical industry with fast route to clinical evaluation of low GWP pMDIs 3 May 2024 -- Holmes Chapel and Manchester, UK -- Bespak, a leading contract development and manufacturing organisation (CDMO) focused on orally inhaled and nasal drug-device combination products, and The Medicines Evaluation Unit (MEU), one of the UK’s leading contract...
Bespak confirms completion of inhaled and nasal drug delivery business separation from Recipharm to focus on the transition to low GWP pMDIs
Spin-out unites three sites to create a leading global CDMO as further significant investments announced at Holmes Chapel site 2 April 2024 – Holmes Chapel, UK, and Stockholm, Sweden – (Business Wire) — Bespak today announced the completion of the transaction to separate Recipharm’s former Advanced Delivery Systems Business Unit from the Recipharm Group to...
